

Washington State Health Care Authority

Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029 https://www.hca.wa.gov/about-hca/prescription-drug-program

1/16/2024

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2024 and April 1, 2024:

Targeted Immune Modulator (TIM)			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
adalimumab-ADAZ	adalimumab-ADAZ auto injector	Not	Yes
adalimumab-BWWD	Hadlima [®] syringe	participating	Yes
	Hadlima Pushtouch [®] auto injector		Yes
apremilast	Otezla [®] tablet		Yes
etanercept	Enbrel [®] kit		Yes
-	Enbrel [®] solution		Yes
	Enbrel [®] syringe		Yes
	Enbrel Mini [®] solution		Yes
	Enbrel Sureclick [®] auto injector		Yes
	Enbrel Sureclick [®] solution		Yes
guselkumab	Tremfya [®] syringe		Yes
secukinumab	Cosentyx [®] solution		Yes
	Cosentyx [®] syringe		Yes
	Cosentyx Sensoready Pen [®] auto injector pen		Yes
tofacitinib citrate	Xeljanz [®] solution		Yes
	Xeljanz [®] tablet		Yes
	Xeljanz XR [®] tablet		Yes
ustekinumab	Stelara [®] solution		Yes
	Stelara [®] syringe		Yes
The effect of this recommendation is to make Tremfya preferred 1/1/2024 on the WA PDL, and to make Hadlima and adalimumab-ADAZ preferred and Humira, Rinvoq, and Skyrizi non-preferred 4/1/2024 on the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our website.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at <u>leta.evaskus@hca.wa.gov</u>.

Sincerely,

Bunal Sullem

Donna Sullivan Chief Pharmacy Officer Clinical Quality and Care Transformation Washington State Health Care Authority